Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 105

Similar articles for PubMed (Select 24004943)

1.

A cost-effectiveness analysis of a 10-valent pneumococcal conjugate vaccine in children in six Latin American countries.

Martí SG, Colantonio L, Bardach A, Galante J, Lopez A, Caporale J, Knerer G, Gomez JA, Augustovski F, Pichon-Riviere A.

Cost Eff Resour Alloc. 2013 Aug 30;11(1):21. doi: 10.1186/1478-7547-11-21.

2.

Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines.

Tyo KR, Rosen MM, Zeng W, Yap M, Pwee KH, Ang LW, Shepard DS.

Vaccine. 2011 Sep 2;29(38):6686-94. doi: 10.1016/j.vaccine.2011.06.091. Epub 2011 Jul 13.

PMID:
21745516
3.

Cost-effectiveness and cost utility analysis of three pneumococcal conjugate vaccines in children of Peru.

Gomez JA, Tirado JC, Navarro Rojas AA, Castrejon Alba MM, Topachevskyi O.

BMC Public Health. 2013 Oct 30;13:1025. doi: 10.1186/1471-2458-13-1025.

4.

Modeling the impact of a new vaccine on pneumococcal and nontypable Haemophilus influenzae diseases: a new simulation model.

De Wals P, Black S, Borrow R, Pearce D.

Clin Ther. 2009 Oct;31(10):2152-69. doi: 10.1016/j.clinthera.2009.10.014.

PMID:
19922887
5.

Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program.

Wisløff T, Abrahamsen TG, Bergsaker MA, Løvoll Ø, Møller P, Pedersen MK, Kristiansen IS.

Vaccine. 2006 Jul 17;24(29-30):5690-9. Epub 2006 May 5.

PMID:
16735083
6.

Outcomes and costs associated with PHiD-CV, a new protein D conjugate pneumococcal vaccine, in four countries.

Talbird SE, Taylor TN, Knoll S, Frostad CR, García Martí S.

Vaccine. 2010 Nov 19;28 Suppl 6:G23-9. doi: 10.1016/j.vaccine.2010.06.016.

PMID:
21075266
7.

Cost-Effectiveness Evaluation of the 10-Valent Pneumococcal Non-typeable Haemophilus influenzae Protein D Conjugate Vaccine and 13-Valent Pneumococcal Vaccine in Japanese Children.

Shiragami M, Mizukami A, Leeuwenkamp O, Mrkvan T, Delgleize E, Kurono Y, Iwata S.

Infect Dis Ther. 2014 Dec 20. [Epub ahead of print]

8.

Comparing health outcomes and costs of general vaccination with pneumococcal conjugate vaccines in Sweden: a Markov model.

By A, Sobocki P, Forsgren A, Silfverdal SA.

Clin Ther. 2012 Jan;34(1):177-89. doi: 10.1016/j.clinthera.2011.12.007.

PMID:
22284997
9.

Cost effectiveness of pneumococcal vaccination among Dutch infants: economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines.

Rozenbaum MH, Sanders EA, van Hoek AJ, Jansen AG, van der Ende A, van den Dobbelsteen G, Rodenburg GD, Hak E, Postma MJ.

BMJ. 2010 Jun 2;340:c2509. doi: 10.1136/bmj.c2509.

10.

Cost-effectiveness analysis of the 10- and 13-valent pneumococcal conjugate vaccines in Argentina.

Urueña A, Pippo T, Betelu MS, Virgilio F, Giglio N, Gentile A, Jimenez SG, Jáuregui B, Clark AD, Diosque M, Vizzotti C.

Vaccine. 2011 Jul 12;29(31):4963-72. doi: 10.1016/j.vaccine.2011.04.111. Epub 2011 May 27.

PMID:
21621575
11.

Cost-effectiveness of the CRM-based 7-valent pneumococcal conjugated vaccine (PCV7) in Argentina.

Giglio ND, Cane AD, Micone P, Gentile A.

Vaccine. 2010 Mar 8;28(11):2302-10. doi: 10.1016/j.vaccine.2009.12.070. Epub 2010 Jan 9.

PMID:
20064478
12.

Economic evaluation of second generation pneumococcal conjugate vaccines in Norway.

Robberstad B, Frostad CR, Akselsen PE, Kværner KJ, Berstad AK.

Vaccine. 2011 Nov 3;29(47):8564-74. doi: 10.1016/j.vaccine.2011.09.025. Epub 2011 Sep 21.

PMID:
21945264
13.

New vaccines against otitis media: projected benefits and cost-effectiveness.

O'Brien MA, Prosser LA, Paradise JL, Ray GT, Kulldorff M, Kurs-Lasky M, Hinrichsen VL, Mehta J, Colborn DK, Lieu TA.

Pediatrics. 2009 Jun;123(6):1452-63. doi: 10.1542/peds.2008-1482.

PMID:
19482754
14.
15.

Cost-effectiveness of new pneumococcal conjugate vaccines in Turkey: a decision analytical model.

Bakır M, Türel O, Topachevskyi O.

BMC Health Serv Res. 2012 Nov 9;12:386. doi: 10.1186/1472-6963-12-386.

16.

Cost-effectiveness of a 10- versus 13-valent pneumococcal conjugate vaccine in Denmark and Sweden.

Klok RM, Lindkvist RM, Ekelund M, Farkouh RA, Strutton DR.

Clin Ther. 2013 Feb;35(2):119-34. doi: 10.1016/j.clinthera.2012.12.006. Epub 2013 Jan 10.

PMID:
23312274
17.

Cost effectiveness of pneumococcal conjugate vaccination against acute otitis media in children: a review.

Boonacker CW, Broos PH, Sanders EA, Schilder AG, Rovers MM.

Pharmacoeconomics. 2011 Mar;29(3):199-211. doi: 10.2165/11584930-000000000-00000. Review.

PMID:
21250759
18.

The cost-effectiveness of pneumococcal conjugate vaccination in Australia.

Butler JR, McIntyre P, MacIntyre CR, Gilmour R, Howarth AL, Sander B.

Vaccine. 2004 Mar 12;22(9-10):1138-49.

PMID:
15003641
19.

Cost-effectiveness analysis of 10- and 13-valent pneumococcal conjugate vaccines in Peru.

Mezones-Holguin E, Canelo-Aybar C, Clark AD, Janusz CB, Jaúregui B, Escobedo-Palza S, Hernandez AV, Vega-Porras D, González M, Fiestas F, Toledo W, Michel F, Suárez VJ.

Vaccine. 2015 May 7;33 Suppl 1:A154-66. doi: 10.1016/j.vaccine.2014.12.039.

PMID:
25919156
20.

Cost-effectiveness of 2 + 1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada.

Earnshaw SR, McDade CL, Zanotti G, Farkouh RA, Strutton D.

BMC Infect Dis. 2012 Apr 24;12:101. doi: 10.1186/1471-2334-12-101.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk